Multiple Myeloma, Phase III
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects With Light Chain (AL) Amyloidosis
Volunteers
Health Professionals
What is the purpose of this trial?
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in patients with AL amyloidosis in Mayo Stage IV.
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.
Principal Investigator
Sub-Investigators
- Agatha Hecht
- Alexis Walker
- Alison Johnson
- Andrea Brennan
- Armand Russo, MD
- Brooke Chaves
- Catherine Wei, MD
- David Witt, MD
- Erica Stevens
- Harold Tara Jr, MD
- James Vredenburgh, MD
- Jane Kanowitz, MD
- Jeremy Kortmansky, MD
- Justin Persico, MD
- Kathleen Fenn, MD
- Kayla Martello
- Kristen Hoxie
- Larisa Fleysher
- Leena Rahmat
- Madeline Santiago
- Michael Cohenuram, MD
- Natalia Neparidze, MD
- Neal Fischbach, MD
- Noffar Bar, MD
- Osarugue Otasowie
- Pawan Karanam, MD
- Renee Moye
- Sabrina Browning, MD
- Sara Anastasio, RN
- Sudhanshu Mulay, MD
- Syed Ali
- Syed Bilgrami, MBBS
- Tara Anderson
- Vidya Kesavan
- Virginia Syombathy
- Last Updated04/07/2024
- Study HIC#2000030933